Evidence map›Paper›PMID 37587368›Full record

ArticlePediatric research2024

Clinical and healthcare utilization outcomes during the 6 months following COVID infection in children.

Aliza S Gordon, Sonali Shambhu, Yaoxuan Xia, Peter N Bowers, Sue Sloop, Eugene Hsu

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Aliza S GordonPublic Policy Institute, Elevance Health, Inc., Indianapolis, IN, 46204, USA. Aliza.gordon@elevancehealth.com.ORCID 0000-0003-4565-0771
Sonali ShambhuPublic Policy Institute, Elevance Health, Inc., Indianapolis, IN, 46204, USA.
Yaoxuan XiaCarelon Research, Wilmington, DE, 19801, USA.
Peter N BowersPopulation Health Management Support, Elevance Health, Inc., Indianapolis, IN, 46204, USA.
Sue SloopHealth Economics, Elevance Health, Inc., Indianapolis, IN, 46204, USA.
Eugene HsuMedicare Clinical Operations, Elevance Health, Inc., Indianapolis, IN, 46204, USA.
Covance (United States) · USPublic Policy Institute of California · USWilmington University · US

Funding

Elevance Health, Inc
6 · The paper itself

Abstract

backgroundWe aimed to identify the impact of COVID infection in children in the US prior to vaccine availability on clinical and healthcare utilization outcomes within 6 months of infection.

methodsUsing claims data from a large national insurer, we identified 223,842 children with a COVID diagnosis in May 2020-March 2021 and matched them to 223,842 children with a COVID test and no diagnosis. We compared the two cohorts' outcomes during the 6 months after infection/test.

resultsUncommon acute adverse events occurring in <0.5% of cases, including MIS-C (relative risk (RR) = 45.2), myocarditis (RR = 10.3), acute heart failure (RR = 2.14), sepsis (RR = 2.02), and viral pneumonia (RR = 2.43) were more frequent in the COVID cohort (all p < 0.001). Development of arrhythmias (RR = 1.24, p < 0.001) and atherosclerotic cardiovascular disease (RR = 1.41, p = 0.007) were more common in the COVID group, while behavioral health disorders were less common (RR = 0.94, p < 0.001). Lab testing and imaging were slightly higher in the COVID group (RR ranging 1.05-1.11 depending on the service and timeframe), though medical costs did not increase.

conclusionSevere disease and diagnoses of new conditions are rare in children following COVID infection. We observed an increase in cardiac complications, though they may not last long term. IMPACT: Few studies have analyzed the association between COVID infection and medium-term outcomes in children. Our study of >447,000 geographically and socioeconomically diverse children in the US found that uncommon acute adverse events, including myocarditis, MIS-C, and acute heart failure, were more frequent in children with COVID than matched controls, and development of arrhythmias and cardiovascular disease were 1.2 and 1.4 times more common, respectively. Six-month healthcare utilization was similar between cohorts. We provide data on the risks of COVID in children, particularly with respect to cardiac complications, that decision makers may find useful when weighing the benefits and harms of preventive measures.

Indexed as

COVID-19Heart FailureMyocarditisSystemic Inflammatory Response SyndromeChildHumansPatient Acceptance of Health Care

Identifiers

PMID37587368
OpenAlexW4385852553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.